New Approaches to Target Tetrahydrobiopterin Effects in Cardiovascular Disease Pathogenesis and Treatment

A molecule best known for helping blood vessels relax is now being found to drive cardiovascular disease through entirely separate mechanisms inside heart muscle and immune cells. This matters because current treatments for high blood pressure, inflammation, and heart attack damage largely ignore this newly discovered role. The molecule, tetrahydrobiopterin (BH4), is essential for producing nitric oxide—a signal that widens blood vessels. But researchers have now shown that BH4 also influences cellular redox signalling, metabolism, and gene expression in ways that can promote disease. The problem is that existing drugs cannot target these harmful effects without also blocking BH4’s beneficial role in blood vessels. If this project succeeds, it could lead to therapies that selectively interrupt BH4’s disease-driving actions in heart and immune cells while leaving its vascular function intact. The researchers are particularly interested in BH4’s overlap with the folate cycle—a metabolic pathway already targeted by cheap, widely available folate compounds. A clearer mechanistic understanding could allow clinicians to repurpose these existing drugs for specific patient groups, such as those with hypertension or ischaemia-reperfusion injury, where BH4-driven damage is most pronounced. This is fundamental science with a clear translational path, not a near-term treatment.